Mr. Andre Larente reports

DIAGNOS ANNOUNCES GRANT OF STOCK OPTIONS

Diagnos Inc. has granted an aggregate number of 1.55 million stock options to its directors and officers.

Stock options vest at 50 per cent per year, commencing with the first anniversary of the grant. The date of the grant is Oct. 3, 2024. The exercise price of the stock options granted has been established at 37 cents per common share. The expiry date to which the stock options can be exercised is Oct. 3, 2029.

The grant remains subject to regulatory compliance, including TSX Venture Exchange, acceptance. All moneys quoted in this press release shall be stated and paid in lawful money of Canada.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.